Literature DB >> 7492938

Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients.

M Zierhut1, J Saal, U Pleyer, I Kötter, H Dürk, G Fierlbeck.   

Abstract

Behçet's disease (BD) is a systemic disease of unknown etiology, characterized by multiple organ involvement. Although its incidence is high in the Mediterranean countries and in Japan, BD is not often found in German patients. We therefore compared the epidemiological and clinical involvement of BD in 39 patients of German and of Mediterranean origin. The first manifestation was oral aphthosis in 72% of patients, followed by eye involvement (62%), skin lesions (25%), and arthritic problems (23%). Eventually, all our patients developed oral aphthosis. Whereas Germans had eye involvement in only 55% of cases (Mediterraneans, 71%), they came up with venous thrombosis or thrombophlebitis more often (64%) as compared with Mediterraneans (29%). The first ocular symptom was anterior uveitis in 87.5% of patients; the visual prognosis was poor due to occlusive retinopathy. Among 22 eyes of 12 patients, 16 had a visual acuity of 0.1 or less after 5 years of disease. We found a similar association with human leukocyte antigen B5 (HLA-B5) in the German patients (66.7%) and in the Mediterranean group (54.4%). There was no significantly higher HLA-B5 association with the uveitis or arthritis type. These results demonstrate a few differences between the two ethnic groups but illustrate that in Germans the disease also has a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492938

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  10 in total

1.  [Epidemiology of ocular involvement in Adamantiades-Behçets disease].

Authors:  C E Kneifel; A-K Köhler; A Altenburg; C C Zouboulis; L Krause
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

2.  Primary association of HLA-B51 with Behçet's disease in Ireland.

Authors:  D J Kilmartin; A Finch; R W Acheson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 3.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany.

Authors:  Lothar Krause; Anne-Katrin Köhler; Andreas Altenburg; Nestor Papoutsis; Christos C Zouboulis; Uwe Pleyer; Andrea Stroux; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

5.  [Epidemiology and clinical aspects of Adamantiades-Behçet disease in Gemany. Current data].

Authors:  A Altenburg; A Mahr; C Maldini; C E Kneifel; L Krause; I Kötter; T Stache; N G Bonitsis; C C Zouboulis
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

6.  [Typical and atypical ocular manifestations of Behçet's disease].

Authors:  N Stübiger; U Pleyer
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

7.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

8.  [Familial uveitis. Forms and incidence in patients at the University Eye Hospital Tubingen].

Authors:  C M E Deuter; N Stübiger; K Siepmann; M Derse; M Zierhut
Journal:  Ophthalmologe       Date:  2003-09       Impact factor: 1.059

9.  [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].

Authors:  C M E Deuter; I Kötter; I Günaydin; M Zierhut; N Stübiger
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

Review 10.  A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease.

Authors:  Michele Figus; Chiara Posarelli; Timothy G Albert; Rosaria Talarico; Marco Nardi
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.